Please find attached Virbac half-year report 2026
news
Virbac : Half-Year report 2026
The Daily Recap
The day in focus. Delivered to your inbox.
A concise daily briefing of key stories, insights and developments, selected by our editorial team.
By subscribing, you agree to our Privacy Policy. Unsubscribe at any time.More to Read
news
ONLYOFFICE 10.0 brings AI tools, modular apps, and stronger security to its open-source office suite
SINGAPORE , Oct. 10, 2026 -- ONLYOFFICE presents the major autumn update 10.0 with context-aware AI tools directly in the editors, new modular Apps, and a significant security upgrade. Around 50 new features and more than 1,000 fixes for the online, desktop, and mobile editors. AI that understands your documents, in every editor ONLYOFFICE 10.0 puts context-aware AI inside the document, spreadsheet, presentation, and PDF editors. A dedicated AI tab with built-in chat lets teams draft, summarize, translate, clean and format without leaving the file or copying content into a separate tool.
news
LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that it has granted to Dr. Susan G. Kozauer, the new Chief Medical Officer and Joseph Miller, the new Chief Financial Officer of LB Pharmaceuticals, equity awards outside of, but subject to the terms a
news
CytoMed Therapeutics Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
SINGAPORE, Oct. 09, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (the “Company”) (NASDAQ: GDTC), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies, today announced that on October 6, 2026, the Company received a notice from the staff of the Nasdaq Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that for the last
news
Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes
SAN CARLOS, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced concurrent underwritten public offerings of 8,584,375 shares of common stock at a public offering price of $64.00 per share, pre-funded warrants to purchase 400,000 shares of common stock at a public offering price of $63.999 per pre-funded warrant and $575 million aggregate principal amount of 1.50% convertible s
news
NurExone Advances Optic Nerve Injury Program Toward Larger-Animal Study, Following Positive Preclinical Results
Preclinical Results at Sheba Medical Center Demonstrate Retinal Recovery with NurExone’s Exosome-based Lead Candidate TORONTO and HAIFA, Israel, Oct. 09, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biopharmaceutical company developing exosome-based regenerative therapies, today announced new preclinical findings demonstrating the therapeutic benefits of its naïve exosomes (exosomes without added therapeutic cargo) and
news
AB Science today reports its revenues for the first half of 2026 and provides an update on its activities
PRESS RELEASE AB SCIENCE REPORTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2026 AND KEY EVENTS OF THE PERIOD Change in AB Science's governance and implementation of a new strategy Appointment of Stéphane Ledermann as Chairman and Chief Executive Officer In-depth overhaul of the Company's organisation and strategy Priority given to the development of a new quality assurance system Web conference to be held on Wednesday 14 October 2026 at 6:00 pm to present the Company's new ambitions in detail
news
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressure target of - In the Explore-OSA trial in participants with obstructive sleep apnea, lorundrostat 50 mg taken once daily in the evening achieved clinically meaningful reductions in morning systolic blood pressure with no measurable change in apnea-hypopnea indices - RADNOR, Pa., Oct. 09, 2026 (GLOBE
news
HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
Communication with FDA at recent Type B meeting provided clear guidance for next steps to prepare IND application to support first-in-human clinical study in cancer HCW11-018b is Company’s lead candidate in its second-generation T-Cell Engager Program constructed using proprietary non-FC based TRBC platform technology Manufacturing of cGMP material for clinical trials is underway IND application remains on track to be filed in 1H 2027 MIRAMAR, Fla., Oct. 09, 2026 (GLOBE NEWSWIRE) -- HCW Biologic
Comments (0)
Login to join the conversation
Login / RegisterNo comments yet. Be the first to comment!